Search results
Q1 2024 Acurx Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 58 minutes agoHaving robust preclinical, clinical and manufacturing data to date, we submitted, in January, a formidable information package to the FDA, along with a request for an end of Phase< ...
NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis
Clinical Trials Arena via Yahoo Finance· 17 hours agoPhaseV will analyse NeuroSense’s Phase II ALS trial data, and results from these will inform Phase...
Earnings call: Protalix BioTherapeutics Q1 2024 financial results By Investing.com
Investing.com· 5 days agoThe company announced the expansion of their Phase I study for PRX-115, a recombinant uricase...
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
CBS 47 Fresno· 22 hours agoThis cash position, and other secured funding sources, provide a runway through Q1 2026. In Q1 2024, Ryvu announced the initiation of two Phase II studies ...
Earnings call: Acumen Pharmaceuticals reports progress in ALTITUDE-AD study By Investing.com
Investing.com· 1 day agoAcumen Pharmaceuticals, in its Q1 2024 earnings call, detailed the initiation of the ALTITUDE-AD ...
Raheem Morris: Kirk Cousins is "pretty much full-go" in Phase II
ProFootball Talk on NBC Sports via Yahoo Sports· 5 days agoSpeaking to the media at the start of rookie minicamp on Friday, head coach Raheem Morris said that...
Pipeline Moves: Phase III completion for Corcept’s relaorilant
Clinical Trials Arena via Yahoo Finance· 3 days agoMeanwhile, Regeneron has completed a Phase II trial of its candidate mibavademab in lipodystrophy...
Recce Pharmaceuticals doses first participants in next cohort Phase I/II UTI/Urosepsis rapid...
Proactive Investors· 24 hours agoRecce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has dosed the first participants in the next cohort...
Genprex dosing subjects in trial of combination therapy for small-cell lung cancer
Clinical Trials Arena via Yahoo Finance· 19 hours agoShould the Phase I study proceed without dose-limiting toxicities, the highest dose tested will be...
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
Pharmaceutical Technology via Yahoo Finance· 3 days agoThe Swiss pharma company will also be eligible to receive “tiered double-digit royalties” should...
